387 related articles for article (PubMed ID: 11268285)
1. Intercellular transfer of the virally derived precursor form of acid alpha-glucosidase corrects the enzyme deficiency in inherited cardioskeletal myopathy Pompe disease.
Pauly DF; Fraites TJ; Toma C; Bayes HS; Huie ML; Hirschhorn R; Plotz PH; Raben N; Kessler PD; Byrne BJ
Hum Gene Ther; 2001 Mar; 12(5):527-38. PubMed ID: 11268285
[TBL] [Abstract][Full Text] [Related]
2. Adenovirus-mediated transfer of the acid alpha-glucosidase gene into fibroblasts, myoblasts and myotubes from patients with glycogen storage disease type II leads to high level expression of enzyme and corrects glycogen accumulation.
Nicolino MP; Puech JP; Kremer EJ; Reuser AJ; Mbebi C; Verdière-Sahuqué M; Kahn A; Poenaru L
Hum Mol Genet; 1998 Oct; 7(11):1695-702. PubMed ID: 9736771
[TBL] [Abstract][Full Text] [Related]
3. Complete correction of acid alpha-glucosidase deficiency in Pompe disease fibroblasts in vitro, and lysosomally targeted expression in neonatal rat cardiac and skeletal muscle.
Pauly DF; Johns DC; Matelis LA; Lawrence JH; Byrne BJ; Kessler PD
Gene Ther; 1998 Apr; 5(4):473-80. PubMed ID: 9614571
[TBL] [Abstract][Full Text] [Related]
4. Multiple muscles in the AMD quail can be "cross-corrected" of pathologic glycogen accumulation after intravenous injection of an [E1-, polymerase-] adenovirus vector encoding human acid-alpha-glucosidase.
McVie-Wylie AJ; Ding EY; Lawson T; Serra D; Migone FK; Pressley D; Mizutani M; Kikuchi T; Chen YT; Amalfitano A
J Gene Med; 2003 May; 5(5):399-406. PubMed ID: 12731088
[TBL] [Abstract][Full Text] [Related]
5. Improved efficacy of gene therapy approaches for Pompe disease using a new, immune-deficient GSD-II mouse model.
Xu F; Ding E; Liao SX; Migone F; Dai J; Schneider A; Serra D; Chen YT; Amalfitano A
Gene Ther; 2004 Nov; 11(21):1590-8. PubMed ID: 15356673
[TBL] [Abstract][Full Text] [Related]
6. Long-term efficacy after [E1-, polymerase-] adenovirus-mediated transfer of human acid-alpha-glucosidase gene into glycogen storage disease type II knockout mice.
Ding EY; Hodges BL; Hu H; McVie-Wylie AJ; Serra D; Migone FK; Pressley D; Chen YT; Amalfitano A
Hum Gene Ther; 2001 May; 12(8):955-65. PubMed ID: 11387060
[TBL] [Abstract][Full Text] [Related]
7. Glycogen storage in multiple muscles of old GSD-II mice can be rapidly cleared after a single intravenous injection with a modified adenoviral vector expressing hGAA.
Xu F; Ding E; Migone F; Serra D; Schneider A; Chen YT; Amalfitano A
J Gene Med; 2005 Feb; 7(2):171-8. PubMed ID: 15515143
[TBL] [Abstract][Full Text] [Related]
8. Recombinant human acid alpha-glucosidase corrects acid alpha-glucosidase-deficient human fibroblasts, quail fibroblasts, and quail myoblasts.
Yang HW; Kikuchi T; Hagiwara Y; Mizutani M; Chen YT; Van Hove JL
Pediatr Res; 1998 Mar; 43(3):374-80. PubMed ID: 9505277
[TBL] [Abstract][Full Text] [Related]
9. Correction of the enzymatic and functional deficits in a model of Pompe disease using adeno-associated virus vectors.
Fraites TJ; Schleissing MR; Shanely RA; Walter GA; Cloutier DA; Zolotukhin I; Pauly DF; Raben N; Plotz PH; Powers SK; Kessler PD; Byrne BJ
Mol Ther; 2002 May; 5(5 Pt 1):571-8. PubMed ID: 11991748
[TBL] [Abstract][Full Text] [Related]
10. Retroviral transfer of acid alpha-glucosidase cDNA to enzyme-deficient myoblasts results in phenotypic spread of the genotypic correction by both secretion and fusion.
Zaretsky JZ; Candotti F; Boerkoel C; Adams EM; Yewdell JW; Blaese RM; Plotz PH
Hum Gene Ther; 1997 Sep; 8(13):1555-63. PubMed ID: 9322088
[TBL] [Abstract][Full Text] [Related]
11. Enhanced efficacy of an AAV vector encoding chimeric, highly secreted acid alpha-glucosidase in glycogen storage disease type II.
Sun B; Zhang H; Benjamin DK; Brown T; Bird A; Young SP; McVie-Wylie A; Chen YT; Koeberl DD
Mol Ther; 2006 Dec; 14(6):822-30. PubMed ID: 16987711
[TBL] [Abstract][Full Text] [Related]
12. Correction of glycogen storage disease type II by enzyme replacement with a recombinant human acid maltase produced by over-expression in a CHO-DHFR(neg) cell line.
Martiniuk F; Chen A; Donnabella V; Arvanitopoulos E; Slonim AE; Raben N; Plotz P; Rom WN
Biochem Biophys Res Commun; 2000 Oct; 276(3):917-23. PubMed ID: 11027569
[TBL] [Abstract][Full Text] [Related]
13. Isolation and characterisation of a recombinant, precursor form of lysosomal acid alpha-glucosidase.
Fuller M; Van der Ploeg A; Reuser AJ; Anson DS; Hopwood JJ
Eur J Biochem; 1995 Dec; 234(3):903-9. PubMed ID: 8575451
[TBL] [Abstract][Full Text] [Related]
14. Replacing acid alpha-glucosidase in Pompe disease: recombinant and transgenic enzymes are equipotent, but neither completely clears glycogen from type II muscle fibers.
Raben N; Fukuda T; Gilbert AL; de Jong D; Thurberg BL; Mattaliano RJ; Meikle P; Hopwood JJ; Nagashima K; Nagaraju K; Plotz PH
Mol Ther; 2005 Jan; 11(1):48-56. PubMed ID: 15585405
[TBL] [Abstract][Full Text] [Related]
15. Fully deleted adenovirus persistently expressing GAA accomplishes long-term skeletal muscle glycogen correction in tolerant and nontolerant GSD-II mice.
Kiang A; Hartman ZC; Liao S; Xu F; Serra D; Palmer DJ; Ng P; Amalfitano A
Mol Ther; 2006 Jan; 13(1):127-34. PubMed ID: 16169280
[TBL] [Abstract][Full Text] [Related]
16. Antibody-mediated enzyme replacement therapy targeting both lysosomal and cytoplasmic glycogen in Pompe disease.
Yi H; Sun T; Armstrong D; Borneman S; Yang C; Austin S; Kishnani PS; Sun B
J Mol Med (Berl); 2017 May; 95(5):513-521. PubMed ID: 28154884
[TBL] [Abstract][Full Text] [Related]
17. Correction of glycogenosis type 2 by muscle-specific lentiviral vector.
Richard E; Douillard-Guilloux G; Batista L; Caillaud C
In Vitro Cell Dev Biol Anim; 2008; 44(10):397-406. PubMed ID: 18810562
[TBL] [Abstract][Full Text] [Related]
18. Correction of glycogen storage disease type II by an adeno-associated virus vector containing a muscle-specific promoter.
Sun B; Zhang H; Franco LM; Brown T; Bird A; Schneider A; Koeberl DD
Mol Ther; 2005 Jun; 11(6):889-98. PubMed ID: 15922959
[TBL] [Abstract][Full Text] [Related]
19. Neonatal gene transfer using lentiviral vector for murine Pompe disease: long-term expression and glycogen reduction.
Kyosen SO; Iizuka S; Kobayashi H; Kimura T; Fukuda T; Shen J; Shimada Y; Ida H; Eto Y; Ohashi T
Gene Ther; 2010 Apr; 17(4):521-30. PubMed ID: 20033064
[TBL] [Abstract][Full Text] [Related]
20. Synergistic Efficacy from Gene Therapy with Coreceptor Blockade and a β2-Agonist in Murine Pompe Disease.
Han SO; Li S; Bird A; Koeberl D
Hum Gene Ther; 2015 Nov; 26(11):743-50. PubMed ID: 26417913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
